Moderna, Pfizer & Merck: coronavirus vaccines will not be sold at cost price
US labs Pfizer, Merck and Moderna said Tuesday that if they get the new coronavirus vaccine, they will not sell it at cost, during a hearing in the United States Congress.
In contrast, Johnson & Johnson and AstraZeneca have agreed to initially sell their vaccines without profit.
Several companies have received grants of hundreds of millions of dollars from the United States government or other countries, but these agreements do not always come with clauses that limit the maximum price of the doses.
We will not sell at cost, Moderna President Stephen Hoge said in response to a question from a congressman.
This biotech company has developed one of the most advanced experimental vaccines, whose phase 3 trials will begin next week on 30,000 volunteers.
The company received $483 million of public money from the United States to finance research and development, but without a supply contract for the country, Hoge said.
No, we will not sell at cost price, said Julie Gerberding of Merck, who will not have any vaccines ready until at least 2021, and did not sign any supply contracts with Washington.
This is an extraordinary moment and our award will reflect it, added John Young of Pfizer. During the pandemic, we will price our potential vaccine based on the current global health emergency.
But AstraZeneca, a partner at the University of Oxford in developing one of the most advanced vaccines at the moment, already in a phase 3 trial, signed a $1.2 billion contract with the US government's Barda agency, which plans delivery of 300 million doses at cost price.
The European Union signed a similar contract in June.
Johnson & Johnson, also funded by the so-called White House operation "Warp Speed" ($ 456 million), said for its part that the price of more than 1 billion doses would not leave them profit during the emergency phase of the pandemic.
Several companies have received grants of hundreds of millions of dollars from the United States government or other countries, but these agreements do not always come with clauses that limit the maximum price of the doses.
We will not sell at cost, Moderna President Stephen Hoge said in response to a question from a congressman.
This biotech company has developed one of the most advanced experimental vaccines, whose phase 3 trials will begin next week on 30,000 volunteers.
The company received $483 million of public money from the United States to finance research and development, but without a supply contract for the country, Hoge said.
No, we will not sell at cost price, said Julie Gerberding of Merck, who will not have any vaccines ready until at least 2021, and did not sign any supply contracts with Washington.
This is an extraordinary moment and our award will reflect it, added John Young of Pfizer. During the pandemic, we will price our potential vaccine based on the current global health emergency.
But AstraZeneca, a partner at the University of Oxford in developing one of the most advanced vaccines at the moment, already in a phase 3 trial, signed a $1.2 billion contract with the US government's Barda agency, which plans delivery of 300 million doses at cost price.
The European Union signed a similar contract in June.
Johnson & Johnson, also funded by the so-called White House operation "Warp Speed" ($ 456 million), said for its part that the price of more than 1 billion doses would not leave them profit during the emergency phase of the pandemic.
AI Disclaimer: An advanced artificial intelligence (AI) system generated the content of this page on its own. This innovative technology conducts extensive research from a variety of reliable sources, performs rigorous fact-checking and verification, cleans up and balances biased or manipulated content, and presents a minimal factual summary that is just enough yet essential for you to function as an informed and educated citizen. Please keep in mind, however, that this system is an evolving technology, and as a result, the article may contain accidental inaccuracies or errors. We urge you to help us improve our site by reporting any inaccuracies you find using the "Contact Us" link at the bottom of this page. Your helpful feedback helps us improve our system and deliver more precise content. When you find an article of interest here, please look for the full and extensive coverage of this topic in traditional news sources, as they are written by professional journalists that we try to support, not replace. We appreciate your understanding and assistance.